Oragenics, Inc. announced in May 2024 that it entered into a partnership with Avance Clinical, a leading Contract Research Organization (CRO). This collaboration is intended to strengthen the company's ability to execute its upcoming Phase II clinical trial for ONP-002.
The partnership leverages Avance Clinical's expertise in clinical trial management and regulatory pathways. This strategic alliance is expected to streamline the development process for ONP-002, Oragenics' lead candidate for concussion treatment.
Securing a CRO partner is a crucial step for a biotechnology company advancing a drug candidate through clinical phases. This move supports the efficient progression of ONP-002 towards potential market approval.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.